Arvinas (NASDAQ:ARVN) CAO David Loomis Sells 1,016 Shares

Arvinas, Inc. (NASDAQ:ARVN) CAO David Loomis sold 1,016 shares of Arvinas stock in a transaction on Friday, February 13th. The shares were sold at an average price of $11.89, for a total value of $12,080.24. Following the sale, the chief accounting officer directly owned 30,800 shares of the company’s stock, valued at $366,212. This represents a 3.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Arvinas Stock Up 3.3%

Arvinas stock opened at $11.82 on Thursday. The stock has a market cap of $759.08 million, a price-to-earnings ratio of -14.59 and a beta of 1.88. The business has a 50-day simple moving average of $12.38 and a 200 day simple moving average of $10.33. Arvinas, Inc. has a 52 week low of $5.90 and a 52 week high of $19.40.

Key Headlines Impacting Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Upcoming catalyst — Arvinas will host a webcast to report Q4 and full‑year 2025 results on Feb. 24; that event gives management a chance to reset expectations or highlight clinical/pipeline progress, which could drive upside or increased trading volume. Arvinas to Report Q4 and Full Year 2025 Financial Results
• Neutral Sentiment: Short‑interest reporting anomaly — recent short‑interest prints show 0 shares (days‑to‑cover 0.0), which is almost certainly a data error and unlikely to reflect meaningful changes to short positioning; treat these figures cautiously.
• Neutral Sentiment: Institutional & analyst context — multiple funds have modestly adjusted positions recently and Wall Street coverage is mixed (consensus “Hold” with a ~$13.12 target); this background suggests the stock’s longer‑term view remains driven by clinical/pharma news rather than the recent micro trades. MarketBeat ARVN
• Negative Sentiment: Clustered insider selling — several senior insiders sold shares on Feb. 13 at an average price of $11.89: CEO Randy Teel (4,403 shares), CFO Andrew Saik (5,134 shares), CAO David K. Loomis (1,016 shares) and insider Noah Berkowitz (5,685 shares). While sizes are modest relative to institutional holdings, simultaneous sales by top executives often hurt near‑term sentiment and can pressure the stock. SEC filings: Loomis (Loomis Form 4), Berkowitz (Berkowitz Form 4), Saik (Saik Form 4), Teel (Teel Form 4).

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. ProShare Advisors LLC boosted its holdings in Arvinas by 7.2% during the 4th quarter. ProShare Advisors LLC now owns 14,827 shares of the company’s stock valued at $176,000 after acquiring an additional 993 shares during the period. Intech Investment Management LLC lifted its position in Arvinas by 3.6% in the third quarter. Intech Investment Management LLC now owns 32,653 shares of the company’s stock valued at $278,000 after purchasing an additional 1,125 shares during the last quarter. MetLife Investment Management LLC boosted its stake in shares of Arvinas by 4.3% during the fourth quarter. MetLife Investment Management LLC now owns 33,810 shares of the company’s stock valued at $401,000 after purchasing an additional 1,381 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Arvinas by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock worth $271,000 after purchasing an additional 2,122 shares during the last quarter. Finally, Oxford Asset Management LLP grew its holdings in shares of Arvinas by 15.5% in the second quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock worth $123,000 after purchasing an additional 2,242 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wedbush reissued a “neutral” rating and issued a $9.00 price target on shares of Arvinas in a research note on Thursday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arvinas in a research report on Monday, December 22nd. Wall Street Zen cut Arvinas from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Stephens lifted their price target on Arvinas from $14.00 to $15.00 and gave the stock an “overweight” rating in a research note on Monday, November 10th. Finally, Citigroup upgraded Arvinas from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $10.00 to $15.00 in a report on Tuesday, January 6th. Ten equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Arvinas presently has a consensus rating of “Hold” and an average target price of $13.12.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.